Sernova Corp. announced that its principal clinical investigator, Dr. Piotr Witkowski, presented additional positive preliminary safety and efficacy data at the 2021 American Society of Transplant Surgeons Winter Symposium. Sernova's Cell PouchTMtransplanted with insulin producing cells in patients with type 1 diabetes continues to show persistent islet function and clinically meaningful improvement in measures of glucose control. Dr. Witkowski highlighted the following key points in his presentation: 5 of 7 patients are currently enrolled in the study. 5 of 7 patients have been implanted with the Cell Pouch; 3 of 7 patients have received their first/one islet transplant; 2 of 7 patients have received their first and second islet transplant; The remaining 2 patients are actively being pre-screened to complete trial enrolment. The overall objective of the study is to assess the safety, tolerability, and efficacy of the Cell Pouch with insulin-producing islets. In addition to other criteria, prior to entry into the study, the patients must demonstrate long-standing type 1 diabetes with severe hypoglycemic unawareness episodes and no glucose-stimulated C-peptide circulating in their bloodstream. Importantly, these patients are showing defined clinical benefit with a clinically meaningful reduction in daily injectable insulin requirement, along with the following additional ongoing efficacy indicators: Absence of life threatening severe hypoglycemic events; Sustained blood levels of C-peptide (a biomarker for insulin produced by cells in the Cell Pouch); Reduction in HbA1c (a measure of long-term glucose control); and, Improvement in overall Continuous Glucose Monitoring (CGM) measured glucose control parameters (e.g., blood glucose `Time in Range'). With the positive clinical benefit achieved in patients with Cell Pouch islets, one patient was later provided a single infusion of islets (portal vein). This top-up to the islets already received in the Cell Pouch contributed to this patient achieving and sustaining insulin independence. This patient has now been insulin free (requiring no injectable insulin) for nine months with optimal glucose control.